Peptide selected by phage display increases survival of SH‐SY5Y neurons comparable to brain‐derived neurotrophic factor

Nafian, Fatemeh; Rasaee, Mohammad Javad; Yazdani, Shahin; Daftarian, Narsis; Soheili, Zahra‐Soheila; Azad, Babak Kamali Doust

doi:10.1002/jcb.28036

Cited by 5 publications

(6 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RNYK also indicated neuroprotective activities at an optimum concentration of 5 ng/ml compared with BDNF at 50 ng/ml. This observation is in agreement with our previous studies showing that RNYK could prevent neuronal degeneration of ATRA-treated SH-SY5Y with equal efficacy to or even better than BDNF (Nafian, Rasaee, Yazdani, Daftarian, et al, 2018;.…”

Section: Discussionsupporting

confidence: 93%

“…Therefore, at high doses and in long‐term delivery, BDNF may not increase cell survival or reverse neurodegeneration. Recently, we have demonstrated that RNYK as a novel BDNF mimetic can be an alternative to circumvent these problems (Nafian, Rasaee, Yazdani, Daftarian, et al, 2018; Nafian, Rasaee, Yazdani, & Soheili, 2018). RNYK has been selected from a phage‐displayed random peptide library with high‐affinity binding to NTRK2 and neurotrophic activities.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A lab‐on‐a‐chip model of glaucoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

Glaucoma is a collective term used to define a group of neurodegenerative processes affecting the entire visual pathway best distinguished by progressive, irreversible destruction, and death of retinal ganglion cells (RGCs). The disease spectrum is estimated to affect more than 100 million people worldwide by the year of 2040 (Tham et al., 2014). The primary risk factor for progression and development of glaucoma is elevated intraocular pressure (IOP). IOP is regulated by the balance between aqueous humor secretion into

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Introductionmentioning

confidence: 99%

A lab‐on‐a‐chip model of glaucoma

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…This previously confirmed that RNYK can mimic BDNF activities in vitro at an optimum concentration of 5 ng ml −1 . RNYK prevented neuronal degeneration of ATRA-treated SH-SY5Y with equal efficacy to or even better than BDNF at 50 ng ml −1 (Nafian et al, 2018). In the current study, RNYK indicated a neuroprotective effect comparable to BDNF on primary RGCs under both normal and elevated pressures.…”

Section: Discussionmentioning

confidence: 99%

“…To achieve this aim, we designed pressure chips in which HP could be modulated with the added benefits of higher speed, greater precision and finer control than previous EHP systems. We studied RGC survival under normal versus elevated hydrostatic pressures and also compared survival of these cells when treated with a neuroprotective growth factor (brain-derived neurotrophic factor, BDNF) or a mimicry peptide, named RNYK, as a putative agonist of neurotrophic tyrosine kinase receptor type 2 (NTRK2) (Nafian et al, 2018). BDNF is a well-known neuroprotectant and a potent therapeutic candidate for neurodegenerative diseases.…”

Section: Introductionmentioning

confidence: 99%

A lab-on-a-chip model of glaucoma

Nafian

Azad

Yazdani

et al. 2019

Preprint

Self Cite

View full text Add to dashboard Cite

statement: Glaucoma-on-a-chip offers the advantages of allowing controlled experimental conditions, 15 preliminary targeting of a specific cell type or pathway involved in glaucoma and investigating putative 16 neuroprotective agents prior to assessment in animal models. 17 Abstract 18We developed a glaucoma-on-a-chip (GOC) model to evaluate the viability of retinal ganglion cells (RGCs) 19 against high pressure and neuroprotective treatments. A three-layered chip consisting of interconnecting 20 microchannels and culture wells was fabricated based on simulation of physical parameters. The bottom surface of 21 the wells was mechanically modified by air plasma and coated with different membranes to model an extracellular 22 microenvironment. SH-SY5Y used as model cells to determine the best supporting membrane which was revealed 23 to be PDL/laminin. RGCs were isolated from postnatal Wistar rats and purified by magnetic assisted cell sorting up 24 to 70%. The cultured RGCs were exposed to normal (15 mmHg) or elevated pressure (33 mmHg) for 6, 12, 24, 36 25 and 48 hours, with and without adding brain-derived-neurotrophic factor (BDNF) or a novel BDNF mimetic (named 26 RNYK). RGC survival rates were 85, 78, 70, 67 and 61% under normal pressure versus 40, 22, 18, 12 and 10% under 27 high pressure at 6, 12, 24, 36 and 48 hours, respectively (P<0.0001). BDNF and RNYK reduced the rate of RGC 28 death under both normal and elevated pressures, two-fold approximately (p<0.01-0.0001). 29 42 et al., 1995; Vecino and Sharma, 2011). Without sequential treatments, the duration of IOP elevation is 43 transient in these models. Precise control over IOP elevation is difficult and certain problems may occur; these include 44 intraocular inflammation, irreversible mydriasis, IOP variability, hyphema, reduced visibility of optic discs, corneal 45 opacity, and scleral burns (Johnson and Tomarev, 2010; Rudzinski and Saragovi, 2005). While in vivo animal models 46 are indispensable to determine what events occur in live organisms, these strategies typically involve poorly defined 47 377 Acevedo, A. D., Bowser, S. S., Gerritsen, M. E. and Bizios, R. (1993). Morphological and proliferative 378 responses of endothelial cells to hydrostatic pressure: role of fibroblast growth factor. Journal of Cellular Physiology. 379 157, 603-614. Shareef

show abstract

“…Glaucoma‐on‐a‐chip provided an optimized glaucomatous condition, when subjected to a physiological microenvironment for proper communication of RGCs. [ 80 ]…”

Section: Organ‐on‐chip Models For Degenerative Diseasesmentioning

confidence: 99%

Degenerative disease‐on‐a‐chip: Developing microfluidic models for rapid availability of newer therapies

Jahagirdar

Bangde

Jain

et al. 2021

Biotechnology Journal

View full text Add to dashboard Cite

Background: Understanding the pathophysiology of degenerative diseases pertaining to nervous system, ocular region, bone/cartilage, and muscle are still being comprehended, thus delaying the availability of targeted therapies.Purpose and Scope: Newer micro-physiological systems (organ-on-chip technology) involves development of more sophisticated devices, modelling a range of in vitro human tissues and an array of models for diseased conditions. These models expand opportunities for high throughput screening (HTS) of drugs and are likely to be rapid and cost-effective, thus reducing extensive usage of animal models. Conclusion:Through this review article, we aim to present an overview of the degenerative disease models that are presently being developed using microfluidic platforms with the aim of mimicking in vivo tissue physiology and micro-architecture. The manuscript provides an overview of the degenerative disease models and their potential for testing and screening of possible biotherapeutic molecules and drugs. It highlights the perspective of the regulatory bodies with respect to the established-on chip models and thereby enhancing its translational potential.

show abstract

Peptide selected by phage display increases survival of SH‐SY5Y neurons comparable to brain‐derived neurotrophic factor

Cited by 5 publications

References 66 publications

A lab‐on‐a‐chip model of glaucoma

A lab‐on‐a‐chip model of glaucoma

A lab-on-a-chip model of glaucoma

Degenerative disease‐on‐a‐chip: Developing microfluidic models for rapid availability of newer therapies

Contact Info

Product

Resources

About